BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas

NCT07258680 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

114

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T-cell Lymphoma

Interventions

DRUG: Doxorubicin
DRUG: Vincristine
DRUG: Etoposide
DRUG: cyclophosphamide
DRUG: Prednisone
DRUG: Brentuximab Vedotin (Bv)

Sponsor

N.N. Petrov National Medical Research Center of Oncology